Bartlett & Co. LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 70.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 163,546 shares of the company’s stock after purchasing an additional 67,472 shares during the period. Bartlett & Co. LLC’s holdings in Merck & Co., Inc. were worth $13,767,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Titan Capital Management LLC CA bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth about $25,000. LFA Lugano Financial Advisors SA raised its position in shares of Merck & Co., Inc. by 250.0% in the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares in the last quarter. JJJ Advisors Inc. bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth about $27,000. Cumberland Partners Ltd bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth about $40,000. Finally, Fusion Family Wealth LLC raised its position in shares of Merck & Co., Inc. by 268.2% in the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares in the last quarter. 74.95% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Richard R. Deluca sold 6,427 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $85.09, for a total value of $546,873.43. Following the completion of the sale, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.27% of the company’s stock.
Several research analysts have recently weighed in on MRK shares. JPMorgan Chase & Co. set a $96.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Thursday, October 10th. Credit Suisse Group reissued a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Societe Generale set a $105.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Bank of America started coverage on Merck & Co., Inc. in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price objective for the company. Finally, ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $95.13.
Shares of Merck & Co., Inc. stock opened at $83.25 on Thursday. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $87.35. The firm has a market capitalization of $217.48 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 1.84 and a beta of 0.54. The business has a 50-day simple moving average of $84.03 and a 200 day simple moving average of $82.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The business had revenue of $12.40 billion during the quarter, compared to analyst estimates of $11.59 billion. During the same period in the previous year, the company posted $1.19 EPS. The firm’s revenue was up 14.9% compared to the same quarter last year. On average, sell-side analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current year.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.